Biotech Vertex Pharmaceuticals stock tumbled on news of disappointing drug data. CEO Reshma Kewalramani paid nearly $4 ...

And one of the best ways to cash in on that is to invest in stocks that can exceed the market's performance. Two that look ...

A joint venture led by locally based REIT Diversified Healthcare Trust (NASDAQ: DHC) has received $1 billion for the refinancing of the Vertex Pharmaceuticals headquarters facility in Boston. A ...

The RMR Group secured a $1 billion refinancing for Vertex Pharmaceuticals' Boston Seaport headquarters, a five-year, interest ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q2 CY2025 results beating Wall Street’s revenue expectations, ...

Vertex Pharmaceuticals’ second quarter 2025 results exceeded Wall Street’s expectations, but the market responded sharply ...

Thousands of Massachusetts biotech employees face job losses amid industry turmoil. Laid-off workers share their struggles ...

Vertex Pharmaceuticals' unchanged guidance and disappointing trial outcomes for its investigative pain relief treatment led ...

Vertex Pharmaceuticals' Seaport headquarters buildings have been refinanced for $1 billion, putting a ten-figure value on an ...

The biotechnology industry is split between two very different types of companies. On one side are the large, blue-chip leaders like Amgen Inc. (ticker: AMGN), Gilead Sciences Inc.

Vertex Pharmaceuticals Incorporated's stock drop is overblown. With strong CF revenue, pipeline potential, & insider ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $200.0 and $460.0 for Vertex Pharmaceuticals, spanning the last ...